Aveo Oncology's Fotivda receives FDA approval

The U.S. Food and Drug Administration (FDA) approved AVEO Oncology’s Fotivda (tivozanib) for adults with relapsed or refractory advanced renal cell carcinoma (RCC) in people who have had two or more previous systemic therapies. The FDA’s decision comes over three years after the European Union approved the drug in August 2017.